Short‐term cost‐utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9)

Pollock, R.F., Heller, S. orcid.org/0000-0002-2425-9565, Pieber, T.R. et al. (6 more authors) (2019) Short‐term cost‐utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9). Diabetes, Obesity and Metabolism, 21 (7). pp. 1706-1714. ISSN 1462-8902

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2019 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, http://creativecommons.org/licenses/by/4.0/ which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Keywords: cost‐effectiveness; insulin analogues; insulin therapy; pharmaco‐economics
Dates:
  • Accepted: 26 March 2019
  • Published (online): 29 March 2019
  • Published: July 2019
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 22 Jan 2020 16:28
Last Modified: 22 Jan 2020 16:28
Status: Published
Publisher: Wiley
Refereed: Yes
Identification Number: https://doi.org/10.1111/dom.13730
Related URLs:

Share / Export

Statistics